Keywords: csl, 3b, takeover, talecris, may, blocked, ftc
CSL $3B takeover of Talecris may be blocked by US FTC
Article | 28 May 2009
Australia's CSL, the world's second-largest plasma products maker, may have its $3.1-billion takeover of USA-based Talecris Biotherapeutics blocked by the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- US Supreme Court says patent settlement can "sometimes" be illegal
- Negative US patent ruling for Novo Nordisk on Prandin
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
